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SUMMARY Cockroaches cause allergic diseases and are closely linked with the development of asthma. Bla g 1 
is one of the major allergen proteins produced by German cockroaches. It consists of tandem repeats of approxi-
mately 100 amino acids. The aim of the present study was to identify linear IgE-binding epitopes of Bla g 1.02. RT-
PCR was used to clone a cDNA sequence encoding Bla g 1.02 (EF202179) which shared 98.6-99.8% identity with 
a previously reported Bla g 1.02 (AF072220). To investigate IgE binding regions, five separate but overlapping Bla 
g 1.02 peptide fragments (A: aa 1-111, B: aa 102-215, C: aa 206-299, D: aa 289-403, E: aa 394-491) were ampli-
fied and cloned. The full-length and five peptide fragments were overexpressed in Pichia pastoris and E. coli, re-
spectively, and their IgE binding reactivities were measured by ELISA using 37 serum samples isolated from cock-
roach-sensitized patients. The sera of 24 patients (64.9%) recognized the full-length Bla g 1.02 recombinant pro-
tein. Among 19 selected serum samples, 11 sera (57.9%) reacted to peptide fragment A, 5 sera (31.3%) to B, 4 
sera (21.1%) to C, 9 sera (47.4%) to D, and 10 sera (52.6%) to peptide fragment E. IgE-binding epitopes are found 
to be distributed to each tandem repeat of Bla g 1. The combination of peptide fragments A, D, and E may able to 
detect all Bla g 1-sensitized subjects. We suggest that these peptide fragments may be useful in allergy diagnosis 
and the design of novel immunotherapeutics. 
 
. 
 
Cockroaches produce major indoor allergens 
that induce IgE-mediated allergic diseases such as al-
lergic rhinitis and asthma.1  Exposure to high levels 
of cockroach allergens in children who live in cities 
and in low-income housing has been reported to 
cause such respiratory problems.2-3 Patients with 
cockroach allergies exhibited high levels of serum 
IgE antibodies as compared to general asthmatics 
and patients suffering from mite asthma.4-5 Seven 
German cockroach (Blattella germanica) allergens 
have been thus far identified and characterized.  
These allergens are derived from the intestinal tract, 
ovaries, ootheca, exuvia, and feces of the cock-
roach.6-7  
 
Bla g 1 is a German cockroach allergen that 
consists of several tandem repeats of approximately 
100 amino acids and displays IgE-binding frequency 
in 30-77% of cockroach allergic patients.7,8  It con-
tains more than 2 duplexes, each containing 2 con-
secutive amino acid repeats that share 26-29% ho-
mology, and each duplex represents a distinct mo-
lecular unit of Bla g 1.8 Bla g 1 isoallergens (cDNA 
clones Bla g 1.01 and Bla g 1.02) show 70-72% nu-
cleotide sequence homology to the antigenically 
cross-reactive Periplaneta americana (American 
cockroach) group 1 allergen (Per a 1).9 Exposure to 
122  YI, ET AL. 
Bla g 1 is a high risk factor for sensitivity to German 
cockroaches.10-11  Bla g 1 is located primarily within 
the cockroach alimentary tract, mainly the midgut, 
and indeed Northern hybridizations using various gut 
tissues have demonstrated that Bla g 1 is produced 
exclusively by midgut cells.12 Quantitative analyses 
of Bla g 1 mRNA expression and Bla g 1 protein 
levels in adult females showed that both are closely 
linked to the reproductive cycle of female cock-
roaches. Large amounts of Bla g 1 are excreted in 
cockroach feces. Fecal production closely follows 
the food consumption patterns in B. germanica, with 
Bla g 1 content following a similar cyclic rise and 
fall as reflected by food intake and the production of 
feces.13  
 
Bla g 1 could serve at least two physiological 
functions, both of which are associated with food in-
take. Firstly, Bla g 1 is secreted from the midgut epi-
thelium via the rough endoplasmic reticulum and 
may play a role in digestion.9 Bla g 1 shares 35–40% 
amino acid sequence identity with the Anopheles 
gambiae ANG12 and Aedes aegypti AEG12 proteins, 
both of which are produced in the female mosquito 
midgut and undergo temporal changes in expression 
relative to the acquisition of blood meal.14 Secondly, 
Bla g 1 may have an important structural role in the 
midgut. A recent report showed that cockroach aller-
gen-like microvillar membrane proteins from Tene-
brio molitor possess a 37% amino acid sequence 
identity with Bla g 1.15 Since Bla g 1 fecal concentra-
tions are highest as feeding decreases, microvilli that 
contains Bla g 1 may be sloughed off after large food 
boluses pass through the midgut. 
 
Diverse pharmacotherapeutic approaches are 
used in an attempt to alleviate allergic symptoms in 
patients. However, only allergen specific immuno-
therapy is believed to have continuous curative ef-
fects.16 In order to precisely diagnose and treat aller-
gic reactions, high quality cockroach extracts are 
necessary. However, extracts are prone to contamina-
tion with other allergens (that subjects are not sensi-
tized to) and various proteolytic enzymes which can 
affect the stability of allergens and may cause in-
flammatory responses in their own right.17-18  Such 
problems may be overcome by the use of highly pu-
rified recombinant allergens that are produced in suf-
ficient quantities for treatment.19   
 
B cell and T cell epitopes should be analyzed 
for immunotherapy using recombinant allergens. 
Following the identification of IgE-binding epitopes, 
allergens that exert a low IgE binding capacity can 
then be synthesized for immunotherapy by incorpo-
rating amino acids substitutions within epitope re-
gions.20 Although Bla g 1 is an important factor in 
patient allergies toward cockroaches, studies into B 
cell and T cell epitope recognition by Bla g 1 have 
not yet been carried out.  
 
We have previously described the amino acid 
sequence polymorphisms of Bla g 1.02, with the ma-
jor variant submitted to GenBank (accession number 
EF202179).21 The objective of the present study was 
to determine the location of IgE-binding epitopes for 
the predominant form of Bla g 1.02 through the use 
of recombinant proteins. IgE-binding epitopes of Bla 
g 1 may assist in improving cockroach allergy diag-
nosis and in the development of novel therapeutic 
approaches.  
 
MATERIALS AND METHODS 
 
Total RNA isolation and cDNA synthesis  
 
Total RNA was isolated from 10 adult fe-
male B. germanica using the TRIzol reagent (Invi-
trogen Life Technologies, Carlsbad, CA, USA) ac-
cording to the manufacturer’s instructions. Briefly, 
tissue from each cockroach was homogenized in 1 
ml of TRIzol reagent and homogenates extracted us-
ing chloroform. The total RNA was precipitated with 
isopropyl alcohol, washed in 75% ethanol, and fi-
nally resuspended in RNase-free water. First strand 
cDNA was synthesized from 5 µg of total RNA us-
ing AMV reverse transcriptase (Promega, Madison, 
WI, USA) and an oligo(dT18) primer.  
 
RT-PCR and molecular cloning of Bla g 1.02 
cDNA 
 
RT-PCR was performed using a forward (5’-
GCCATAGAATTCCTCAATAAC) and reverse 
primer (5’-GAAACTTTCTTAGATATGGAAC) 
which were designed based on the Bla g 1.02 cDNA 
sequence obtained from GenBank (accession number 
AF072220). RT-PCR was carried out under thermal 
cycling conditions as follows: an initial step at 95°C 
for 5 minutes, followed by 35 cycles of 94°C for 30 
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seconds, 58°C for 30 seconds and 72°C for 2 min-
utes, with a final extension of 9 minutes at 72°C. The 
amplified products were ligated into a pGEM-T Easy 
vector (Promega) and sequenced in both directions 
(Solgent Co. Ltd., Daejeon, Korea). All DNA se-
quences were aligned and compared with the Gen-
Bank Bla g 1.02 cDNA sequence and deduced into 
amino acid sequences, using the SDSC Biology 
Workbench program (http://workbench.sdsc.edu/).  
 
P. pastoris expression of full-length Bla g 1.02 
 
The cDNA sequence encoding Bla g 1.02 
cloned in pGEM-T Easy vector21 was amplified us-
ing PCR, forward primer Blag102FF (CTCGAG-
CATCATCATCATCATCATGCCATAGAATTCCT-
CAAT) and reverse primer Blag102RF (GCGGCC-
GCTGATGATGATGATGATGAGACAATCCAAA-
GAGT). The underlined sequences correspond to 
XhoI and NotI sites, respectively, and six histidine 
codons were incorporated into both primers. The 
PCR product was digested with XhoI and NotI and 
subcloned into pPIC9 (Invitrogen Life Technologies). 
GS115 cells were then transformed with SalI-
linearized plasmids using a Pichia EasyCom Kit (In-
vitrogen Life Technologies). His+ transformants were 
selected on RDB plates (1.34% yeast nitrogen base 
without amino acids, 1 M sorbitol, 1% dextrose, 4 x 
10-5% biotin, and 0.005% each of L-glutamic acid, 
L-methionine, L-lysine, L-leucine, and L-isoleucine).  
Individual clones were grown in buffered methanol-
complex medium (1% yeast extract, 2% peptone, 
100 mM potassium phosphate, pH 6.0, 1.34% yeast 
nitrogen base without amino acid, 4 x 10-5 % biotin, 
0.5% methanol) for 5 days at 220 rpm, 30°C, with 
0.05% methanol (v/v) added every 24 hours. Har-
vested supernatants were diluted with lysis buffer 
(10 mM imidazole, 300 mM NaCl, 50 mM 
NaH2PO4·H2O, pH 8.0) and recombinant proteins pu-
rified using nickel nitrilotriacetic acid (Ni-NTA) 
resin (Qiagen, Valencia, CA, USA), according to 
manufacturer’s instructions.   
 
Expression of Bla g 1.02 fragments in E. coli 
 
Five overlapping Bla g 1.02 fragments were 
generated (A: aa 1-111, B: aa 102-215, C: aa 206-
299, D: aa 289-403, and E: aa 394-491)(Fig. 1) using 
PCR with the specific primers shown in Table 1.  
PCR amplicons were ligated into the expression vec-
tor pET28b (Novagen, Madison, WI) following di-
gestion with BamHI and XhoI. Recombinant plas-
mids were transformed into E. coli. BL21 (DE3) 
cells and the expression of Bla g 1.02 fragments in-
duced with 1 mM isopropyl thio-β-D-galactoside at 
37°C. After 4 hours, cultures was harvested and cells 
resuspended in lysis buffer (6 M urea, 5 mM imida-
zole, 0.5 M NaCl, and 20 mM Tris-HCl, pH 7.9) and 
the peptides purified using Ni-NTA resin according 
to the manufacturer’s instructions.  
 
SDS-PAGE and quantitative analyses
 
Protein measurements were conducted using 
the Bradford assay (Bio-Rad, Hercules, CA). Puri-
fied full-length recombinant Bla g 1.02 and the pro-
 
Table 1 Oligonucleotide primers used for the amplification of Bla g 1.02 gene fragments 
 
Name Sequence 
Bla g 1.02  A F: 5’-GGATCCGGCCATAGAATTCCTCAA  
 R: 5’-CTCGAGAAATATCTGGTGGATGAG  
Bla g 1.02  B F: 5’-GGATCCGCACATAATTGAACTCAT  
 R: 5’-CTCGAGTCTGCGGAGGTGTTTACG  
Bla g 1.02  C F: 5’-GGATCCGCCAGTCACAGCACGTAA  
 R: 5’-CTCGAGGAAAATTTGGTGGATGAG  
Bla g 1.02  D F: 5’-GGATCCGCATATAATTGAACTCAT  
 R: 5’-CTCGAGTCTGCGGACATGTTTGCG  
Bla g 1.02  E F: 5’-GGATCCGCCTGCCACAGGTCGCAA  
R: 5’-CTCGAG ATGAGACAATCCAAAGAG  
 
Underlined regions in forward (F) and reverse  (R) sequences indicate BamH1 and XhoI sites, respectively. 
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tein fragments were separated on 5-20% gradient 
SDS-PAGE gels (Invitrogen Life Technologies) and 
stained with Coomassie brilliant blue R250.  
 
Serum samples 
 
Sera were obtained from 37 patients (age 
range, 5-58 years; average age 32.7 years) (Table 2) 
at the Allergy Clinic at Yonsei University College of 
Medicine, Seoul, Korea. The diagnosis of allergic 
symptoms was based on a skin prick test and patient 
history. Normal serum samples were obtained from 
subjects who showed a negative reaction to skin 
prick tests. Informed consent was obtained from all 
individuals prior to blood collection. 
 
Table 2  IgE reactivities of human sera against recombinant Bla g 1.02 
 
Serial No. Sexa Age Diagnosis OD450b 
P1 M 24 Bronchial asthma 0.0750c 
P2 F 52 Dermatitis 0.0780 
P3 M 30 Urticaria 0.0615 
P4 M 35 Anaphylatic shock 0.0650 
P5 M 56 Asthma 0.0625 
P6 F 9 Rhinitis 0.0645 
P7 F 15 Rhinitis/dermatitis 0.0685 
P8 M 20 Dermatitis 0.0800 
P9 M 21 Dermatitis 0.1475 
P10 M 48 Dyspnea 0.0730 
P11 F 58 Bronchitis 0.0740 
P12 M 52 Allergic asthma, rhinitis 0.1115 
P13 F 46 Allergy cough 0.0830 
P14 M 45 Asthma/rhinitis 0.1045 
P15 M 14 Rhinitis 0.1095 
P16 M 43 Allergic asthma 0.0720 
P17 M 26 Allergic asthma 0.0690 
P18 M 38 Allergic rhinitis 0.0690 
P19 M 49 Conjunctivitis 0.0675 
P20 F 16 Atopic dermatitis 0.0975 
P21 M 49 Allergic asthma 0.0630 
P22 F 15 Rhinitis/dermatitis 0.0655 
P23 M 19 Dermatitis 0.0945 
P24 M 38 Allergic rhinitis 0.0815 
P25 M 26 Atopic dermatitis 0.0790 
P26 M 33 Allergic rhinitis 0.1235 
P27 M 24 Allergic asthma 0.0820 
P28 M 13 Allergic rhinitis 0.0840 
P29 F 45 Allergic asthma 0.0845 
P30 M 20 Asthma 0.0730 
P31 M 23 Allergic asthma, allergic rhiniits 0.0880 
P32 M 22 Allergic asthma, rhiniits, cholinergic urticaria 0.0770 
P33 M 51 Allergic asthma, allergic rhinitis 0.0730 
P34 M 37 Allergic asthma, allergic rhinitis 0.0690 
P35 F 26 Allergic asthma, allergic rhinitis, drug allergy 0.0670 
P36 M 49 Cough 0.0685 
P37 F 22 Allergic eczema 0.0775 
aM, male; F, female; bThe cut-off value was 0.070999; cPositives are indicated by underlined values. 
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Fig. 1  Schematic representation of Bla g 1.02 fragments used for epitope analysis. 
Enzyme-linked immunosorbent assay (ELISA) 
 
Wells of microtiter ELISA plates were coated 
individually with 100 µl of purified full-length Bla g 
1.02 and each protein fragment (10 µg/ml) and incu-
bated at 4°C overnight. Plates were washed three 
times with 0.05% Tween-20 in PBS (PBST). Subse-
quently, wells were blocked with 3% skim milk in 
PBST for 1 hour at 37°C and then washed three 
times with PBST. Fifty microliters of a 1:4 diluted 
sera from cockroach sensitized and non-sensitized 
subjects were added to each well, and the plates were 
incubated at 37°C for 2 hours. After rinsing 3 times 
with PBST, 50 µl of biotinylated goat anti-human 
IgE (1:1,000 dilution) (Vector, Burlingame, CA) was 
added, and followed by incubation at 37°C for 1 hour.  
After rinsing with PBST, streptavidin-peroxidase 
was added and the plates were incubated at 37°C for 
30 minutes. The plates were washed 5 times with 
PBST, and 100 µl of 3,3’,5,5’-tetramethylbenzidine 
substrate solution (Kirkegaard Perry Laboratories, 
Gaithersburg, MD) was added. Following an incuba-
tion for 15 minutes in the dark, reactions were termi-
nated by the addition of 100 µl of 0.5 M H2SO4.  
Absorbances at 450 nm were obtained using an 
ELISA reader. Cut-off values were calculated by fol-
lowing the equation: cut-off = (mean absorbance of 
16 negative sera) + (2 × [standard deviations of 16 
negative sera]). 
 
  
Fig. 2  Expression and purification of recombinant 
full-lenth and fragments of Bla g 1.02. M, 
molecular mass marker (Bio Rad marker 
No.0373); F, Bla g 1.02 full-length; A, Bla g 
1.02 fragment A; B, Bla g 1.02 fragment B; 
C, Bla g 1.02 fragment C; D, Bla g 1.02 
fragment D; and E, Bla g 1.02 fragment E.   
 
 
RESULTS 
 
Expression of recombinant Bla g 1.02 and peptide 
fragments 
 
DNA sequence encoding full-length recom-
binant Bla g 1.02 containing 6 His codons were sub-
cloned into pPIC9 for expression in P. pastoris, 
while five overlapping peptide fragments were ex-
pressed in E. coli (Fig. 1). Protein fragments (A, B, 
C, D, and E) were solubilized from the E. coli in-
soluble fractions using urea, and subsequently puri-
fied using Ni-NTA resin. The theoretical molecular 
weight of the full-length Bla g 1.02 is 57.5 kDa and 
the molecular weight of fragments A, B, C, D and E 
are 17.3, 17.6, 15.4, 17.6, 15.8 kDa, respectively (Fig. 
2). The protein concentrations of the final purified 
preparations were as follows: full-length Bla g 1.02, 
2.90 mg/l; fragment A, 14.69 mg/l; fragment B, 
15.51 mg/l; fragment C, 1.83 mg/l; fragment D, 
17.00 mg/l; and fragment E, 2.24 mg/l. 
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IgE-binding reactivity of full-length recombinant 
Bla g 1.02 
 
ELISA was used to test the reactivity of puri-
fied recombinant Bla g 1.02 with IgE antibodies 
from cockroach allergic patients. Among the 37 sera 
tested, 24 patients (64.9%) showed IgE reactivity to 
full-length recombinant Bla g 1.02. Sera from 
healthy subjects, which were used as negative con-
trols, did not exhibit any IgE reactivity (Fig. 3). 
 
IgE-binding reactivity of Bla g 1.02 peptide frag-
ments and IgE epitope analysis of recombinant 
Bla g 1.02 
  
 
 
Fig. 3  IgE antibody reactivity of human sera 
against recombinant Bla g 1.02. The 
dashed horizontal line indicates the cut-off 
value. ■, Sera from subjects sensitized to 
German cockroach extract (Uni-CAP>0.7); 
◆, Sera from healthy subjects.  
 
Linear IgE-binding epitopes were studied us-
ing Bla g 1.02 fragments that were expressed as five 
separate recombinant overlapping peptides A, B, C, 
D, and E. As mentioned above, 24 from 37 patient 
serum samples demonstrated IgE reactivity to re-
combinant full-length Bla g 1.02 protein. Nineteen 
sera were then used to test IgE reactivities with the 
purified recombinant peptide fragments. Of these, 16 
sera showed positive reactivity to at least one of the 
Bla g 1.02 fragments (Fig. 4). Heterogeneous pat-
terns of IgE reactivities to the Bla g 1.02 allergen 
fragments were found. Only 1 serum sample showed 
IgE-binding reactivity to all five peptide fragments. 
Fragment A showed the highest IgE reactivity fre-
quency (12/19, 63.2%), followed by fragments E 
(10/19, 52.6%), and D (9/19, 47.4%). Fragments B 
and fragment C exhibited low IgE binding frequen-
cies, i.e. 5/19 (26.3%) and 4/19 (21.1%), respectively.  
The strongest IgE reactivity of all fragments among 
all patients tested was observed towards fragment B 
(Table 3).  
 
DISCUSSION 
 
Inhalation of cockroach allergens by sensi-
tized atopic patients causes asthmatic responses. 
Measurements of Bla g 1 levels within the home has 
revealed environmental exposures at > 2 U/g is a 
strong risk factor for sensitization.24-25  Despite its 
importance, the biological functions and mechanisms 
through which allergic reactions are induced to ge-
netically sensitized individuals are not fully under-
stood. In this study, IgE reactivities of Bla g 1 ex-
pressed as a recombinant protein in P. pastoris and 
the overlapping Bla g 1 fragments produced from E. 
coli were assessed in cockroach allergic patients. It is 
 
 
Fig. 4  Binding profile of IgE antibodies to recombinant Bla g 1.02 full length and fragment proteins. Data is 
from 19 serum samples selected from 37 allergic patients. N, pooled sera from 10 healthy non-
allergic subjects. 
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important to note that E. coli has been found to be 
incapable of replicating a recombinant plasmid 
which harbors more than two Bla g 1 duplexes.22 
This observation is due to a recA independent proc-
ess called “replication slippage,” through which E. 
coli removes repeated DNA in plasmids.23  Further-
more, yields of recombinant full-length Bla g 1 in the 
E. coli host are far inferior to the methanol-inducible 
P. Pastoris system. Therefore, P. pastoris was used to 
express the full length protein in the present study.  
However, the recombinant full-length Bla g 1 ex-
pressed in P. pastoris showed the multiple bands on 
the SDS-PAGE. Multiple forms of recombinant Bla 
g 1 were produced possibly by multiple integrations 
of expression cassettes in the yeast genome and sub-
sequent recombinant events between repeats and loss 
of DNA repeat.22 Another possibility is proteolytic 
degradation of the expressed proteins, as addition of 
PMSF and EDTA was reported to reduce slightly the 
production of the low molecular protein bands. 
 
IgE binding reactivities to full-length and 
peptide fragments were determined by ELISA using 
37 serum samples of cockroach allergic patients.  
Sera from 24 patients (64.9%) reacted with rBla g 
1.02, however, the IgE binding intensity was low, a 
feature that has also been noted elsewhere.22 In order 
to analyze linear IgE-binding epitopes, we designed 
five peptide fragments based on established tandem 
repeats of Bla g 1, and measured IgE responses of 
each fragment. Using ELISA, 12 (63.2%), 5 (26.3%), 
4 (21.1%), 9 (47.4%), and 10 (52.6%) were reactive 
to fragments A, B, C, D, and E, respectively. Three 
sera (P2, P10, and P23) reacted to full-length pro-
teins, but did not react to peptide fragments (Table 3). 
This observation may indicate the presence of con-
formational epitopes. Amino acids of fragment B 
may contain cryptic epitopes since three sera reacted 
with this protein B with a higher intensity than the 
full-length peptide. All serum samples that were 
positive to the individual peptide fragments were 
found to be reactive to at least one of the fragments 
A, D, or E.  
 
Upon comparison to the amino acid se-
quences of fragments A, C, and E, twelve amino acid 
differences out of 83 conserved amino acids are ob-
served (Fig. 5A). The IgE responses were similar for 
 
Table 3  IgE binding reactivities of recombinant Bla g 1.02 peptide fragments 
 
 A B C D E F 
P1 0.0670 0.0825 0.0610 0.0790 0.1010 0.100 
P2 0.0625 0.0730 0.0660 0.0650 0.0925 0.0910 
P8 0.0645 0.0785 0.0700 0.0685 0.1035 0.0790 
P9 0.0790 0.1030 0.0735 0.0770 0.0635 0.2775 
P10 0.0645 0.0660 0.0595 0.0690 0.0720 0.0620 
P11 0.0635 0.0725 0.0695 0.0835 0.0760 0.0670 
P12 0.1375 0.2300 0.1015 0.1075 0.0855 0.1505 
P13 0.0780 0.0815 0.0920 0.0965 0.0435 0.0795 
P14 0.0800 0.1010 0.0875 0.0720 0.0660 0.1125 
P15 0.0770 0.0750 0.0760 0.0675 0.1265 0.1105 
P16 0.0690 0.0670 0.0670 0.1135 0.0955 0.0645 
P23 0.0695 0.0675 0.0675 0.0695 0.0910 0.0930 
P25 0.0765 0.0720 0.0800 0.0770 0.0880 0.0730 
P27 0.0830 0.0925 0.0740 0.0620 0.1185 0.0775 
P28 0.0750 0.0650 0.0730 0.0670 0.1030 0.0695 
P31 0.0825 0.0670 0.0800 0.0575 0.1280 0.0760 
P32 0.0755 0.0630 0.0685 0.0535 0.1110 0.0540 
P33 0.0770 0.0685 0.0830 0.0785 0.0870 0.0660 
P37 0.0855 0.2340 0.0945 0.1045 0.1065 0.0770 
 
Each cut-off value is A, 0.075148; B, 0.086673; C, 0.087476; D, 0.074573; E, 0.094261; full length Bla g 1.02 (F), 0.053648.
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fragments A and E, whereas the fragment C exerted 
the lowest IgE reactivity. It is possible that the IgE 
response is altered by the Glu residue at position 266 
of fragment C, which corresponds to Gly at residue 
78 and Gln at residue 454 of the A and E fragments, 
respectively. Comparison of the B and D fragments 
reveals six amino acid differences. The IgE reactivity 
of the fragment D is slightly higher than that of the 
fragment B, which may be caused by the presence of 
an isoleucine (Ile) at position 321 for this fragment 
(Fig. 5B). The influences of a single amino acid sub-
stitution on IgE reactivity have been described for 
Der p 2 and Der f 2.26-28 
 
Previous work has shown that single du-
plexes of Bla g 1 are sufficient in binding IgE, and 
that the presence of an N-terminus in the recombi-
nant Bla g 1 did not affect IgE binding responses.22 
The present study demonstrated poor IgE reactivity 
to a tandem repeat of consecutive amino acids de-
rived from the one duplex. Differential IgE-binding 
patterns to Bla g 1.02 in individual patient sera were 
also observed. 
 
In summary, the peptide fragments A, D, and 
E may be suitable tools in the identification of Bla g 
1-sensitized subjects. Information on Bla g 1.02 IgE-
binding epitopes could be helpful in the diagnosis of 
allergies and may facilitate the design of new immu-
notherapeutic regimes. 
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